Drug adverse event reports (FAERS)
Reports of adverse events and medication errors sent to FDA for drugs and therapeutic biologics. 21,054,159 records; openFDA updated it 2026-11-09. About this dataset
31 records match “exosome”
- INSOMNIA4
- OFF LABEL USE4
- SKIN BURNING SENSATION4
- ARTHRALGIA3
- ERYTHEMA3
- INCORRECT ROUTE OF PRODUCT ADMINISTRATION3
- PAIN3
- PRODUCT USE IN UNAPPROVED INDICATION3
- Dysphagia, Neck pain, Oropharyngeal pain +10
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT
- Incorrect route of product administration, Insomnia, Arthralgia +13
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT, ASPIRIN, REPATHA +1
- Product use in unapproved therapeutic environment, Suspected transmission of an infectious agent via product, Swelling +6
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT
- Feeling abnormal, Product use in unapproved indication, Oropharyngeal discomfort +8
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT
- Injection site pain, Erythema, Scab +7
Drugs: UNAPPROVED DRUG COSMETIC PRODUCTS, STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT, ZYRTEC +5
- Application site mass, Product use issue
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT, Womens Daily Multivitamin, OMEGA 3
- Off label use, Hypoaesthesia
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT, ZINC, VITAMIN C +1
- Off label use, Swelling, Skin mass
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT
- Hypoaesthesia, Product advertising issue, Product label confusion +1
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT, VITAMINS
- Product use in unapproved indication, Inflammation, Scar
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT
- Urticaria
Drugs: SODIUM CHLORIDE, INOSINE\NIACINAMIDE\RIBOFLAVIN\SUCCINIC ACID, PIRACETAM +6
- Aphasia, Immunodeficiency
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT
- Pain in extremity, Peripheral swelling, Immediate post-injection reaction +2
Drugs: STEM CELL, EXOSOME, GROWTH FACTOR OR TISSUE DERIVED UNAPPROVED PRODUCT
- Incorrect route of product administration, Orbital cyst, Swelling face +3
Drugs: STEM CELL, EXOSOME, OR GROWTH FACTOR DERIVED UNAPPROVED PRODUCTS
- Eye swelling, Eyelid thickening, Product use issue
Drugs: STEM CELL, EXOSOME, OR GROWTH FACTOR DERIVED UNAPPROVED PRODUCTS, HYALURONIC ACID
- Product use in unapproved indication, Joint injury
Drugs: STEM CELL, EXOSOME, OR GROWTH FACTOR DERIVED UNAPPROVED PRODUCTS, ESTROGENS, PROGESTERONE +4
- Arthralgia, Pain in extremity, Tremor +8
Drugs: STEM CELL, EXOSOME, OR GROWTH FACTOR DERIVED UNAPPROVED PRODUCTS, LEVOXYL, MONTELUKAST +6
- Stem cell transplant, Product advertising issue, Wrong technique in product usage process +3
Drugs: STEM CELL, EXOSOME, OR GROWTH FACTOR DERIVED UNAPPROVED PRODUCTS
- Off label use, Product use issue, Injection site inflammation
Drugs: STEM CELL, EXOSOME, OR GROWTH FACTOR DERIVED UNAPPROVED PRODUCTS
- Product formulation issue, Self-medication, Vulvovaginal disorder +6
Drugs: STEM CELL, EXOSOME, OR GROWTH FACTOR DERIVED UNAPPROVED PRODUCTS
Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.
How to read this: Each report says someone told FDA an event happened while a product was used. A report does not show the product caused it, and counts rise and fall with how many people report. Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.